Defence Therapeutics Inc. (DTCFF) Research

Defence Therapeutics Inc., a biotechnology firm, is committed to the research and development of innovative biological and biosimilar therapeutic agents for both cancer and infectious diseases. Central to its strategy is the proprietary ACCUM™ technology platform, which ensures the precise and intact delivery of vaccine antigens or antibody-drug conjugates (ADCs) to their intended target cells. The company's development pipeline primarily concentrates on three key areas: dendritic cell-based cancer vaccines, protein-based vaccine formulations for COVID-19 and other infectious illnesses, and various antibody-drug conjugate (ADC) products designed to address different cancers. Founded in 2017, the company originally traded as Accum Therapeutics Inc. before adopting its current name, Defence Therapeutics Inc., in March 2020. Its headquarters are located in Vancouver, Canada.

Market snapshot

Symbol
DTCFF
Price
$0.34
Day change
-5.68%
Market cap
$27.3M
P/E ratio
-4.42x
52-week range
0.3066-0.7787
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Bonus BioGroup Ltd. (BBIXF)
  • Celyad Oncology S.A. (CLYYF)
  • Cynata Therapeutics Limited (CYYNF)
  • Finch Therapeutics Group, Inc. (FNCH)
  • Microbix Biosystems Inc. (MBXBF)
  • MedMira Inc. (MMIRF)
  • Provectus Biopharmaceuticals, Inc. (PVCT)
  • Sernova Corp. (SEOVF)

Open Defence Therapeutics Inc. (DTCFF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.